Trial Profile
An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferon beta-1a (IFN beta-1a, Rebif) therapy in the induction of tolerance to IFN beta in MS patients with neutralising antibodies (NAbs) to subcutaneous IFN beta-1a (Rebif or Avonex).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2011
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary) ; Mitoxantrone (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics
- 02 Aug 2011 New trial record